The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis. All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks.

Inclusion Criteria:

• Male or female patients aged between 20 and 65 years old
• Patients with atopic dermatitis, diagnosed according to Hanifin and Rajka diagnostic criteria
• SCORAD (SCORing Atopic Dermatitis) Score less than 40

Exclusion Criteria:

• Patients presenting symptoms of systemic infection at screening
• Patients who had been treated with oral steroids, oral antibiotics, systemic phototherapy, or immunosuppressants within the last 1 month prior to the investigational product administration
• Patients who had been treated with topical steroids or antibiotics within the last 2 weeks prior to the investigational product administration
• Pregnant women or breastfeeding women
• Women of childbearing potential or women who are planning a pregnancy during the study